Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

1.

Understanding and managing Cognition in the Depressed Patient.

Papakostas GI, Culpepper L.

J Clin Psychiatry. 2015 Apr;76(4):418-25. doi: 10.4088/JCP.13086ah1c.

PMID:
25919832
2.

MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder.

Bilello JA, Thurmond LM, Smith KM, Pi B, Rubin R, Wright SM, Taub F, Henry ME, Shelton RC, Papakostas GI.

J Clin Psychiatry. 2015 Feb;76(2):e199-206. doi: 10.4088/JCP.14m09029.

3.

The nature of placebo response in clinical studies of major depressive disorder.

Papakostas GI, Østergaard SD, Iovieno N.

J Clin Psychiatry. 2015 Apr;76(4):456-66. doi: 10.4088/JCP.14r09297.

PMID:
25700292
4.

Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.

Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, Pisoni A, Papakostas GI.

J Psychiatr Res. 2015 Mar;62:56-61. doi: 10.1016/j.jpsychires.2015.01.007. Epub 2015 Jan 26.

PMID:
25659187
5.

Updates and trends in the treatment of major depressive disorder.

Papakostas GI, Ionescu DF.

J Clin Psychiatry. 2014 Dec;75(12):1419-21. doi: 10.4088/JCP.14ac09610.

PMID:
25551237
6.

An overview of vortioxetine.

Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME.

J Clin Psychiatry. 2014 Dec;75(12):1411-8. doi: 10.4088/JCP.14027ah1. Review.

7.

Association between physician beliefs regarding assigned treatment and clinical response: Re-analysis of data from the Hypericum Depression Trial Study Group.

Chen JA, Vijapura S, Papakostas GI, Parkin SR, Kim DJ, Cusin C, Baer L, Clain AJ, Fava M, Mischoulon D.

Asian J Psychiatr. 2015 Feb;13:23-9. doi: 10.1016/j.ajp.2014.12.002. Epub 2014 Dec 9.

PMID:
25544195
8.

Dr. Mischoulon and colleagues reply.

Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Fava M.

J Clin Psychiatry. 2014 Nov;75(11):e1328-9. doi: 10.4088/JCP.14lr09266a. No abstract available.

PMID:
25470103
9.

Predictors of placebo response in bipolar depression.

Nierenberg AA, Østergaard SD, Iovieno N, Walker RS, Fava M, Papakostas GI.

Int Clin Psychopharmacol. 2015 Mar;30(2):59-66. doi: 10.1097/YIC.0000000000000058.

PMID:
25438027
10.

S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.

Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D.

J Affect Disord. 2014 Aug;164:76-81. doi: 10.1016/j.jad.2014.03.041. Epub 2014 Apr 1.

PMID:
24856557
11.

Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial.

Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, DiPierro M, Cardoos A, Papakostas GI.

Int Clin Psychopharmacol. 2014 Nov;29(6):332-8. doi: 10.1097/YIC.0000000000000039.

PMID:
24815673
12.

Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.

Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM, Fava M.

J Clin Psychiatry. 2014 Aug;75(8):855-63. doi: 10.4088/JCP.13m08947.

PMID:
24813065
13.

A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.

Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, Dording CM, Clain AJ, Durham K, Walker R, Ludington E, Fava M.

J Clin Psychiatry. 2014 Apr;75(4):370-6. doi: 10.4088/JCP.13m08591.

PMID:
24500245
14.
15.

Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice.

Papakostas GI.

J Clin Psychiatry. 2014 Jan;75(1):8-14. doi: 10.4088/JCP.13r08710. Review.

PMID:
24345473
16.

Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.

Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H.

Int Clin Psychopharmacol. 2014 Jan;29(1):16-25. doi: 10.1097/YIC.0000000000000011.

PMID:
24108148
17.

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.

Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ.

Int Clin Psychopharmacol. 2013 Nov;28(6):312-21. doi: 10.1097/YIC.0b013e3283638fbd.

PMID:
23881185
18.

Relationship between sleep disturbance and depression, anxiety, and functioning in college students.

Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, Pedrelli P, Fava M, Pisoni A, Vitolo O, Mischoulon D.

Depress Anxiety. 2013 Sep;30(9):873-80. doi: 10.1002/da.22064. Epub 2013 May 16.

19.

Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy.

Thase ME, Montgomery S, Papakostas GI, Bauer M, Trivedi MH, Svedsäter H, Locklear JC, Gustafsson U, Datto C, Eriksson H.

Int Clin Psychopharmacol. 2013 May;28(3):113-20. doi: 10.1097/YIC.0b013e32835fb971.

PMID:
23485955
20.

A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.

Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M.

J Clin Psychiatry. 2012 Dec;73(12):1541-7. doi: 10.4088/JCP.12m07670.

PMID:
23290327
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk